Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
FibroGen ( (FGEN) ) has provided an announcement.
On November 6, 2025, FibroGen, Inc. received a $6.4 million payment from AstraZeneca, fulfilling the first holdback condition of their share purchase agreement. This follows the August 29, 2025, sale of FibroGen’s China operations to AstraZeneca for approximately $220 million, impacting the company’s financials and strategic focus.
The most recent analyst rating on (FGEN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, persistent losses, and negative equity. While the earnings call provided some positive developments, such as the sale of FibroGen China and new clinical trials, these are overshadowed by the company’s ongoing financial struggles. Technical indicators and valuation metrics also reflect a challenging outlook, with no immediate signs of recovery.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
FibroGen, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of novel therapeutics to treat serious unmet medical needs.
Average Trading Volume: 42,346
Technical Sentiment Signal: Sell
Current Market Cap: $44.48M
For a thorough assessment of FGEN stock, go to TipRanks’ Stock Analysis page.